HIV-associated lymphoma hematopoetic stem cell therapy (Fred Hutchinson Cancer Research Center)

N/A

Report date: 2023/01/12 15:51:44

Base Information

Drug NameHIV-associated lymphoma hematopoetic stem cell therapy (Fred Hutchinson Cancer Research Center)
Drug Alias NameCCR5-shRNA and C46-transduced autologous CD34+ hematopoetic stem cell therapy
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionC-C chemokine receptor type 5 antagonists
TargetsC-C chemokine receptor type 5
Therapy Area/IndicationsLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesFred Hutchinson Cancer Research CenterNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteFred Hutchinson Cancer Research Center
Active IndicationsN/A
Inactive IndicationsLymphoma

Other Information

ATC CodeN/A
Related LinksN/A